(Updates share moves)
** Shares of Telix Pharmaceuticals TLX.AX rise 7.2% to
A$18.44, set for best day since May 31, if gains hold
** Analysts at Jefferies see meaningful upside for TLX
should its products be approved
** Brokerage upgrades price target to A$20.70/shr from
A$15.30, maintains "buy" rating
** Jefferies assumes a successful New Drug Application for
TLX's potential new prostate cancer diagnostic
** A successful new drug application may allow TLX to sell a
second-generation Illuccix in the U.S., and hence retain the
higher-priced pass-through status Illuccix currently has -
Jefferies
** All eight analysts covering the stock rate "Buy" or
higher; their median PT is A$19.00 - LSEG data
** Stock has risen 70.6% YTD, as of last close
(Reporting by Shivangi Lahiri and Ayushman Ojha in Bengaluru)
((shivangi.lahiri@thomsonreuters.com))